Pfizer Has Plenty of Pain to Kill

摘要

PFIZER INC.'S management has long been known for taking calculated risks.And its handling of the painkiller Celebrex has been no different.While analysts believe the drug is essentially dead after a study linked it to increased risk of heart attack,Pfizer is hanging tough.Chairman and Chief Executive Henry A.McRin-nell says there's conflicting data on whether Celebrex really poses a risk and insists he has no plans to withdraw it.